Rovadicitinib

罗伐昔替尼

Report date: 2026/05/20 20:02:01
NMEFirst In Class

Base Information

Drug NameRovadicitinib
Drug Alias Name安煦AnxuTQ-05105CT-1995TQ05105
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitorsRho-associated protein kinase 2 inhibitorsRho-associated protein kinase 1 inhibitors +[4] 
TargetsTyrosine-protein kinase JAK2Rho-associated protein kinase 2Rho-associated protein kinase 1 +[4] 
Therapy Area/IndicationsGraft vs Host DiseaseLymphohistiocytosis, HemophagocyticPrimary Myelofibrosis +[4] 
Global Approved IndicationsPrimary Myelofibrosis
Approved Indications in ChinaPrimary Myelofibrosis
Original Approved Country/TerritoryMainland China
Original Approved Date2026/02/25
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co LtdLianyungang Runzhong Pharmaceutical Co LtdBeijing Centaurus Biopharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSanofi Sa (Sanofi Ag)Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsGraft vs Host DiseaseLymphohistiocytosis, HemophagocyticPrimary Myelofibrosis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank